# Outpatient Cutaneous Wound Care in the United States: Specialty Distribution and Antimicrobial Prescribing Patterns

**Authors:** Ayman Grada, Rithi John Chandy, Jiwon Park, Steven R. Feldman

PMC · DOI: 10.3390/antibiotics15020142 · Antibiotics · 2026-02-01

## TL;DR

This study examines how cutaneous wounds are managed in U.S. outpatient care, focusing on which specialists are involved and how antimicrobials are prescribed.

## Contribution

The study provides national insights into specialty distribution and antimicrobial prescribing patterns for acute and chronic cutaneous wounds.

## Key findings

- Primary care physicians handle most wound visits, while dermatologists manage a smaller share, especially for chronic wounds.
- Antimicrobials are commonly prescribed, with cephalexin being the most frequently used in acute wound visits.
- Chronic wound visits show a more varied antimicrobial profile, including topical treatments like mupirocin and nystatin.

## Abstract

Background: Cutaneous wounds are common in outpatient care, but national patterns of who manages them and how antimicrobials are used remain unclear. Objectives: To characterize outpatient specialty involvement and antimicrobial use for acute and chronic cutaneous wound visits in the United States. Methods: We conducted a retrospective cross-sectional analysis of 2011–2019 National Ambulatory Medical Care Survey (NAMCS) data. Cutaneous wound visits were identified using prespecified ICD-9-CM and ICD-10-CM codes and classified as acute (open or traumatic wounds and burns) or chronic (pressure injuries and lower-limb ulcers). Survey weights were applied to estimate national visit volumes, specialty shares, and antimicrobial utilization patterns. Results: We identified 45.1 million cutaneous wound visits, representing 0.8% of all outpatient visits, of which about two thirds were acute and one third chronic. Primary care physicians accounted for the largest share of wound visits, while dermatologists managed 3.9% of overall wound visits, 2.4% of acute visits, and 7.4% of chronic visits. Among 156.6 million medications recorded at wound visits, antimicrobials represented 13.1% overall, 14.9% in acute visits, and 10.2% in chronic visits. Cephalexin accounted for 32.1% of antimicrobial medications overall and 39.2% in acute visits, whereas chronic wound visits had a more heterogeneous antimicrobial profile that included topical mupirocin, cephalexin, trimethoprim–sulfamethoxazole, and topical nystatin. Conclusions: Outpatient cutaneous wound care in the United States is delivered predominantly by primary care clinicians and relies heavily on a small set of systemic and topical antimicrobials, highlighting opportunities to strengthen antimicrobial stewardship and expand dermatology’s role in chronic wound management.

## Linked entities

- **Chemicals:** cephalexin (PubChem CID 27447), mupirocin (PubChem CID 446596), trimethoprim–sulfamethoxazole (PubChem CID 358641), nystatin (PubChem CID 4568)

## Full-text entities

- **Diseases:** Cutaneous (MESH:D018366), venous leg ulcers (MESH:D014647), fever (MESH:D005334), acute (MESH:D000208), Psoriasis (MESH:D011565), burns (MESH:D002056), Chronic wounds (MESH:D014947), skin and soft tissue infections (MESH:D018461), inflammation (MESH:D007249), thermal injuries (MESH:D020886), swelling (MESH:D004487), coagulase-negative staphylococci (MESH:D064726), cellulitis (MESH:D002481), tenderness (MESH:D063806), systemic (MESH:D015619), allergy (MESH:D004342), NAMCS (MESH:D000090004), erythema (MESH:D004890), infectious diseases (MESH:D003141), colonization (MESH:D003108), pressure injuries (MESH:D003668), Clostridioides difficile infection (MESH:D003015), diabetic foot ulcers (MESH:D017719), limb loss (MESH:D001259), acute or chronic wounds (MESH:D001930), COVID- (MESH:D000086382), cardiovascular diseases (MESH:D002318), infected (MESH:D007239), -limb ulcers (MESH:D014456), wound infection (MESH:D014946), dermatology (MESH:D000168), toxicity (MESH:D064420)
- **Chemicals:** chlorhexidine (MESH:D002710), silver (MESH:D012834), Mupirocin (MESH:D016712), fluconazole (MESH:D015725), trimethoprim-sulfamethoxazole (MESH:D015662), nystatin (MESH:D009761), Cephalexin (MESH:D002506), cephalosporin (MESH:D002511), silver sulfadiazine (MESH:D012837)
- **Species:** Staphylococcus aureus (species) [taxon 1280], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937199/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937199/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937199/full.md

---
Source: https://tomesphere.com/paper/PMC12937199